Bio-Rad Laboratories (BIO) to Release Quarterly Earnings on Wednesday

Bio-Rad Laboratories (NYSE:BIO) is set to issue its quarterly earnings data after the market closes on Wednesday, February 21st. Analysts expect the company to announce earnings of $1.26 per share for the quarter.

Shares of Bio-Rad Laboratories (BIO) opened at $237.36 on Wednesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.06 and a quick ratio of 2.77. Bio-Rad Laboratories has a 12-month low of $186.98 and a 12-month high of $273.87. The stock has a market capitalization of $7,045.50, a price-to-earnings ratio of 300.46, a P/E/G ratio of 1.86 and a beta of 0.97.

Bio-Rad Laboratories announced that its Board of Directors has initiated a share buyback program on Tuesday, November 28th that allows the company to repurchase $250.00 million in outstanding shares. This repurchase authorization allows the medical research company to buy shares of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board believes its stock is undervalued.

A number of research firms have weighed in on BIO. Zacks Investment Research upgraded Bio-Rad Laboratories from a “sell” rating to a “hold” rating in a research report on Tuesday, November 7th. TheStreet upgraded Bio-Rad Laboratories from a “c+” rating to a “b-” rating in a research report on Monday, November 13th. Finally, Wells Fargo & Co restated an “outperform” rating and set a $290.00 price target (up previously from $250.00) on shares of Bio-Rad Laboratories in a research report on Wednesday, November 29th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $277.75.

In other Bio-Rad Laboratories news, VP James R. Stark sold 746 shares of the firm’s stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $270.51, for a total transaction of $201,800.46. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Michael Crowley sold 1,000 shares of the firm’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $258.39, for a total value of $258,390.00. Following the sale, the executive vice president now owns 2,492 shares in the company, valued at approximately $643,907.88. The disclosure for this sale can be found here. Insiders have sold 6,726 shares of company stock worth $1,702,202 in the last 90 days. Company insiders own 28.29% of the company’s stock.

WARNING: “Bio-Rad Laboratories (BIO) to Release Quarterly Earnings on Wednesday” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Earnings History for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with's FREE daily email newsletter.

Leave a Reply